Tokyo, Nov. 8 -- UMIN Clinical Trials Registry (UMIN-CTR) received information related to the study (UMIN000059686) titled 'Treatment Preference Study of Patients with Non-Muscle Invasive Bladder Cancer in Japan' on Nov. 7.
Study Type:
Observational
Primary Sponsor:
Institute - Pfizer Japan Inc.
Condition:
Condition - high-risk non-muscle-invasive bladder cancer (HR-NMIBC)
Classification by malignancy - Malignancy
Genomic information - NO
Objective:
Narrative objectives1 - This study aims to quantify patients' preferences for attributes of investigational ICI agents used in combination with BCG as alternatives to the SOC, BCG alone, for treating patients with HR-NMIBC in Japan.
Basic objectives2 - Others
Eligibility:
Age-lower limit - 18
years-old
<=
Age-upper limit - Not applicable
Gender - Male and Female
Key inclusion criteria - Patients must meet all of the following inclusion criteria to be included in the study:
1. Patients who reside in Japan and speak/read Japanese
2. Patients aged more than 18 years
3. Patients with self-reported HR-NMIBC
4. Patients who are willing and able to provide informed consent
5. Interview only: Patients who are able to participate in a video interview
6. Patient survey only: Patients who are able to access and complete an online survey
Key exclusion criteria - Patients meeting any of the following criteria will not be included in the study:
1. Patient survey only: Patients who participated in the interview survey
Target Size - 105
Recruitment Status:
Recruitment status - Preinitiation
Date of protocol fixation - 2025 Year 09 Month 30 Day
Date of IRB - 2025 Year 10 Month 29 Day
Anticipated trial start date - 2025 Year 11 Month 24 Day
Last follow-up date - 2026 Year 04 Month 30 Day
To know more, visit https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000068272
Disclaimer: Curated by HT Syndication.
